214 related articles for article (PubMed ID: 23727686)
1. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
[TBL] [Abstract][Full Text] [Related]
2. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
[TBL] [Abstract][Full Text] [Related]
3. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
[TBL] [Abstract][Full Text] [Related]
4. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
[No Abstract] [Full Text] [Related]
5. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
[TBL] [Abstract][Full Text] [Related]
6. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
8. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
9. Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
Palacios-Campos A; Gutierrez O; Fabian-Morales E; Avilés A; Candelaria M
Rev Med Chil; 2020 Sep; 148(9):1357-1361. PubMed ID: 33399713
[TBL] [Abstract][Full Text] [Related]
10. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan AM; Gore SD; Komrokji RS
Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
[TBL] [Abstract][Full Text] [Related]
11. [A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Yamada M; Kuroda H; Jomen W; Yoshida M; Miura S; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Arihara Y; Hirako T; Kato J
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2593-7. PubMed ID: 24335378
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
13. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
14. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
[TBL] [Abstract][Full Text] [Related]
15. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5.
Nozawa A; Ozeki M; Yasue S; Endo S; Kadowaki T; Ohnishi H; Muramatsu H; Hama A; Takahashi Y; Kojima S; Fukao T
Int J Hematol; 2020 Nov; 112(5):728-733. PubMed ID: 32519173
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
20. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
